Paper Details

  1. Home
  2. Paper Details

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

Author: BehniaSanaz, BharkSandra L, CassadayRyan D, CowanAndrew J, CoyeHilary, FrommJonathan R, GopalAjay K, LibbyEdward N, LynchRyan C, MartinoChristen N, MorrisKarolyn, PhilipMary, RasmussenHeather, ShadmanMazyar S, ShustovAndrei, SmithStephen D, TillBrian G, UjjaniChaitra S, VoutsinasJenna, WarrenEdus H

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aimed to assess the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma.
Paper Details　
Original Abstract of the Article :
Relapsed or refractory classical Hodgkin lymphoma could be treated with multiagent salvage chemotherapy followed by autologous haematopoietic stem-cell transplantation. The aim of this study is to establish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34329577

データ提供：米国国立医学図書館（NLM）

Dose-Dense Brentuximab Vedotin for Relapsed Hodgkin Lymphoma

The battle against relapsed or refractory classical Hodgkin lymphoma can feel like navigating a vast and unforgiving desert. This study explores the potential of a dose-dense regimen of brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy for patients with this challenging condition. The study aims to assess the safety and efficacy of this novel treatment approach in a single-center, phase 1/2 trial.

A New Oasis in the Desert: Dose-Dense BV-ICE

This study provides preliminary evidence that dose-dense BV-ICE may be a safe and effective treatment option for patients with relapsed or refractory classical Hodgkin lymphoma. The study's findings encourage further research to confirm these initial observations and explore the potential of BV-ICE as a valuable addition to the armamentarium against this disease.

Navigating the Desert of Relapsed Lymphoma

This research emphasizes the need for innovative approaches to treating relapsed or refractory Hodgkin lymphoma. It highlights the potential of combining targeted therapies like brentuximab vedotin with traditional chemotherapy regimens to improve treatment outcomes and provide hope for patients facing this challenging diagnosis.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the desert of relapsed or refractory Hodgkin lymphoma, suggesting that dose-dense BV-ICE may be a promising treatment option for patients. It encourages further research to explore the full potential of this novel approach, ultimately aiming to create a more manageable path for patients battling this difficult disease.

Date :
  1. Date Completed 2021-08-10
  2. Date Revised 2022-08-02
Further Info :

Pubmed ID

34329577

DOI: Digital Object Identifier

NIHMS1730456

Related Literature

Article Analysis
・Effects of brentuximab vedotin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.